Cardiology Clinical Trials

 

Description

 

Type

Enrollment

More

Study:

CONVERGE Post-Approval Study (PAS): Hybrid Convergent of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Longstanding Persistent AF

Cardiac

Open

more 

 

Investigator(s):

Daniel Logsdon, MD (primary), Joseph Wilson, MD, Leon Feldman, MD, Andrew Rubin, MD, Evangelos Diamantakos, DO

 

Contact:

Daniel Logsdon Email:cardiologyresearch@eisenhowerhealth.org or call 760-346-0642

 

Sponsor: 

AtriCure

Study:

Humanitarian Use Device (HUD): Biotronik PK Papyrus Covered Coronary Stent System

Cardiac

Open

more 

 

Investigator(s):

Puneet Khanna, MD (primary)

 

Contact:

Puneet Khanna Email:CardiologyResearch@eisenhowerhealth.org or call 760-340-3911

 

Sponsor: 

BIOTRONIK

Study:

The PROGRESS Trial - Continued Access Protocol

Cardiac

Open

more 

 

Investigator(s):

Andrew Frutkin, MD (primary), Praveen Panguluri, MD, Daniel Logsdon, MD

 

Contact:

Andrew Frutkin Email:cardiologyresearch@eisenhowerhealth.org or call 760-346-0642

 

Sponsor: 

Edwards Lifesciences

Study:

CLOSED TO ENROLLMENT: CHAMPION-AF WATCHMAN FLX versus NOAC for EMbolic Protection in the Management of Patients with Non-Valvular Atrial Fibrillation

Cardiac

Closed

more 

 

Investigator(s):

Leon Feldman, MD (primary), Andrew Rubin, MD, Evangelos Diamantakos, DO

 

Contact:

Leon Feldman Email:CardiologyResearch@eisenhowerhealth.org or call 760-346-0642

 

Sponsor: 

Boston Scientific

Study:

CLOSED TO ENROLLMENT: LANAIS-HF: Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in an Outpatient Setting for Heart Failure

Cardiac

Closed

more 

 

Investigator(s):

Damon Kelsay, MD (primary), Eric Sontz, MD, Leon Feldman, MD, David Choe, MD, Philip Patel, MD

 

Contact:

Damon Kelsay Email:CardiologyResearch@emc.org or call 760-346-0642

 

Sponsor: 

Abbott Medical Devices

Study:

CLOSED TO ENROLLMENT: LIBREXIA-AF: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation.

Cardiac

Closed

more 

 

Investigator(s):

Andrew Rubin, MD (primary), Leon Feldman, MD, Evangelos Diamantakos, DO, Jon Sherman, MD

 

Contact:

Andrew Rubin Email:CardiologyResearch@eisenhowerhealth.org or call 760-346-0642

 

Sponsor: 

Janssen

Study:

CLOSED TO ENROLLMENT: PREFERENCE: A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes

Cardiac

Closed

more 

 

Investigator(s):

Andrew Rubin, MD (primary), Evangelos Diamantakos, DO, Jon Sherman, MD

 

Contact:

Andrew Rubin Email:CardiologyResearch@eisenhowerhealth.org or call 760-346-0642

 

Sponsor: 

Janssen

Study:

CLOSED TO ENROLLMENT: PROGRESS: A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement (TAVR)

Cardiac

Closed

more 

 

Investigator(s):

Andrew Frutkin, MD (primary), Praveen Panguluri, MD, Daniel Logsdon, MD

 

Contact:

Andrew Frutkin Email:CardiologyResearch@eisenhowerhealth.org or call 760-346-0642

 

Sponsor: 

Edwards Lifesciences